The purpose of this study is to test the safety of cabazitaxel, mitoxantrone, and prednisone
(CAMP) in combination at different dose levels and to determine the highest dose that does
not cause bad side effects. The investigators want to find out what effects, good and/or bad,
CAMP has on patients and their metastatic castration-resistant prostate cancer.